<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02992236</url>
  </required_header>
  <id_info>
    <org_study_id>VAS203/I/3/05</org_study_id>
    <nct_id>NCT02992236</nct_id>
  </id_info>
  <brief_title>Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers</brief_title>
  <official_title>Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vasopharm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Winicker Norimed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vasopharm GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analysis of the effect of the NO-Synthase inhibitor VAS203 (6 hours infusion of 10 mg/kg) on
      renal function and perfusion in 16 healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analysis of the effect of i.v. VAS203 on renal function and perfusion in healthy subjects.

      Primary objective:

      Possible adverse effect of VAS203 on the Renal Plasma Flow (RPF) and the Glomerular
      Filtration Rate (GFR) during and after 6 hours of constant-rate iv. infusion of 10 mg/kg
      VAS203.

      Secondary objective:

      To analyse the effects of VAS203 on

        -  filtration fraction

        -  hemodynamics (afferent and efferent resistance, intraglomerular pressure)

        -  markers of kidney injury and renal function

        -  systolic, mean and diastolic brachial blood pressure

        -  Plasma Pharmacokinetic of VAS203 and its first metabolite.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Plasma Flow</measure>
    <time_frame>0, 2h, 4h, 6h and 8 h after start of infusion</time_frame>
    <description>Renal plasma flow measurement by para-Amino-Hippuric-Acid Clearance Method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>0, 2h, 4h, 6h and 8 h after start of infusion</time_frame>
    <description>by para-Amino-Hippuric Acid Clearance Method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine Concentration</measure>
    <time_frame>0, 2h, 4h, 6h, 8h, 10h, 24h and 48h after start of infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Function Impairment in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion (6 hours) of Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAS203</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion (6 hours) of VAS203 (10 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAS203</intervention_name>
    <description>Infusion of NO-Synthase inhibitor VAS203</description>
    <arm_group_label>VAS203</arm_group_label>
    <other_name>Ronopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Infusion of saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent in writing available.

          2. Willing and able to comply with all requirements of the study.

          3. Male, 18 and 45 years (inclusive).

          4. Subject has a body weight between 60 kg and 100 kg, extremes included.

          5. BMI 18 to 27 kg/m2.

          6. Non-smoker

          7. Serum creatinine within reference range (≤1.2 mg/dL) and Cockroft-Gault Clearance &gt; 90
             ml/min

          8. Good general health as judged by the Investigator, as determined by medical history,
             physical examination, vital signs (systolic and diastolic blood pressure and pulse
             rate) and clinical laboratory parameters (clinical chemistry, hematology, and
             urinalysis)

        Exclusion Criteria:

          1. Clinically significant abnormalities in physical examination, vital signs or clinical
             laboratory parameters (according to the Investigator's judgment).

          2. Serum glutamate oxaloacetate transaminase or glutamate-pyruvate transaminase &gt; 2-times
             above the upper limit of normal range.

          3. Subject with Cockcroft-Gault clearance &lt; 90 ml/min.

          4. Clinically significant history of cardiovascular disease or any known present
             cardiovascular disease.

          5. History of clinically significant neurological, gastrointestinal, renal, hepatic,
             psychological, pulmonary, metabolic, endocrine, hematological, or other major
             disorders.

          6. Office blood pressure at screening higher than 160/100 mmHg, or lower than 95/55 mmHg.

          7. Office heart rate at screening after at least 5 minutes outside the range of 50- 99
             beats per minute (inclusive).

          8. Concomitant use of OTC medication within 1 week prior to dosing, except use of
             paracetamol (up to 2 g/day).

          9. Participation in any other clinical study within 30 days prior to inclusion in this -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland E Schmieder, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <results_first_submitted>March 21, 2019</results_first_submitted>
  <results_first_submitted_qc>August 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2019</results_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Cross-over design, all subjects received VAS203 and placebo</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Then VAS203</title>
          <description>Participants first received Placebo (6 hours Infusion of Saline). After a washout period of 4 weeks, they then received VAS203 (6 hours Infusion of 10 mg/kg VAS203).</description>
        </group>
        <group group_id="P2">
          <title>VAS203, Then Placebo</title>
          <description>Participants first received VAS203 (6 hours Infusion of 10 mg/kg VAS203). After a washout period of 4 weeks, they then received Placebo (6 hours Infusion of Saline).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo, Then VAS203</title>
          <description>Participants first received Placebo (6 hours Infusion of Saline). After a washout period of 4 weeks, they then received VAS203 (6 hours Infusion of 10 mg/kg VAS203).</description>
        </group>
        <group group_id="B2">
          <title>VAS203, Then Placebo</title>
          <description>Participants first received VAS203 (6 hours Infusion of 10 mg/kg VAS203). After a washout period of 4 weeks, they then received Placebo (6 hours Infusion of Saline).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="7.9"/>
                    <measurement group_id="B2" value="31.2" spread="7.9"/>
                    <measurement group_id="B3" value="31.2" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Plasma Flow</title>
        <description>Renal plasma flow measurement by para-Amino-Hippuric-Acid Clearance Method</description>
        <time_frame>0, 2h, 4h, 6h and 8 h after start of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Infusion (6 hours) of Saline
Saline: Infusion of saline</description>
          </group>
          <group group_id="O2">
            <title>VAS203</title>
            <description>Infusion (6 hours) of VAS203 (10 mg/kg)
VAS203: Infusion of NO-Synthase inhibitor VAS203</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Plasma Flow</title>
          <description>Renal plasma flow measurement by para-Amino-Hippuric-Acid Clearance Method</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541" spread="85"/>
                    <measurement group_id="O2" value="663" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glomerular Filtration Rate</title>
        <description>by para-Amino-Hippuric Acid Clearance Method</description>
        <time_frame>0, 2h, 4h, 6h and 8 h after start of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VAS203</title>
            <description>Six hours infusion of 10 mg/kg VAS203.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Six hours Infusion of Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate</title>
          <description>by para-Amino-Hippuric Acid Clearance Method</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" spread="15"/>
                    <measurement group_id="O2" value="153.5" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine Concentration</title>
        <time_frame>0, 2h, 4h, 6h, 8h, 10h, 24h and 48h after start of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Infusion (6 hours) of Saline
Saline: Infusion of saline</description>
          </group>
          <group group_id="O2">
            <title>VAS203</title>
            <description>Infusion (6 hours) of VAS203 (10 mg/kg)
VAS203: Infusion of NO-Synthase inhibitor VAS203</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.1"/>
                    <measurement group_id="O2" value="0.94" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Infusion (6 hours) of Saline
Saline: Infusion of saline</description>
        </group>
        <group group_id="E2">
          <title>VAS203</title>
          <description>Infusion (6 hours) of VAS203 (10 mg/kg)
VAS203: Infusion of NO-Synthase inhibitor VAS203</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Dr Rroland Schmieder</name_or_title>
      <organization>Nephrology University Erlangen Germany</organization>
      <phone>+49 9131 8536207</phone>
      <email>roland.schmieder@uk-erlangen.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

